导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.92% | 1316/4773 |
| 近一周 | -1.02% | 1526/5465 |
| 近一月 | -3.59% | 2664/5421 |
| 近一季 | -7.79% | 2972/5231 |
| 近半年 | -3.83% | 2607/4920 |
| 近一年 | 8.92% | 1260/4394 |
| 近两年 | 71.97% | 983/2954 |
| 近三年 | 37.05% | 841/2253 |
| 成立以来 | 107.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.97% 1114/4961 |
18.15% 1411/5312 |
- - |
- - |
| 2025 | 30.08% 1350/4813 |
1.96% 1505/3635 |
1.94% 2008/4076 |
24.04% 1497/4524 |
0.90% 1682/4813 |
| 2024 | 5.90% 1804/3463 |
-2.67% 1403/2808 |
-5.11% 1647/3014 |
15.51% 1696/3129 |
-0.74% 1511/3463 |
| 2023 | -5.39% 734/2656 |
7.71% 531/2280 |
-3.90% 958/2385 |
-4.05% 1048/2515 |
-4.74% 1155/2655 |
| 2022 | -17.38% 582/2207 |
-13.30% 727/1919 |
3.17% 1201/2016 |
-9.84% 318/2113 |
2.45% 933/2208 |
| 2021 | 15.99% 287/1822 |
-1.96% 559/1255 |
9.69% 531/1330 |
4.37% 358/1466 |
3.34% 450/1822 |
| 2020 | 24.94% 625/1250 |
-2.52% 264/1028 |
16.66% 423/1067 |
6.38% 847/1164 |
3.27% 926/1184 |
| 2019 | 26.79% 566/1092 |
30.38% 248/739 |
-10.67% 747/788 |
0.06% 563/850 |
8.79% 289/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 人保中证500指数 VS. 长安沪深300非周期A(740101) |